Roche backs €19M CNS round; CRUK puts £20M into cancer vax; In womb stem cell trial to start

Nick Paul Taylor In this week's EuroBiotech Report, Ysios Capital led a €19.4 million ($ 21.7 million) investment in Minoryx Therapeutics with the support of Roche Venture ...

Trial set for Pfizer in Protonix Medicaid rebate case it inherited

Eric Palmer A federal judge's inclination means Pfizer could remain in the line of fire to pay out more than $ 2 billion. That is the potential liability Pfizer faces for a federal ...

Adaptimmune pockets GSK payouts after tripling size of TCR trial

Nick Paul Taylor Adaptimmune has bagged two milestones from GlaxoSmithKline. The checks landed in Adaptimmune's bank account after it tripled the size of a Phase I/II synovial sarcoma ...

AstraZeneca ties up with little Mirati on another PD-L1 combo trial

John Carroll AstraZeneca's big MedImmune subsidiary has a new partner for its closely-watched PD-L1 checkpoint inhibitor durvalumab (MEDI4736). Little Mirati Therapeutics, which ...

One of Takeda’s big cancer bets flops in a Phase III lymphoma trial

Damian Garde Alisertib, a jewel of Takeda's $ 8.8 billion acquisition of Millennium Pharmaceuticals back in 2008, failed to make the grade in a Phase III lymphoma trial, forcing ...

Singapore to detail trial of MicroVAX novel cancer vaccine

EJ Lane The National Cancer Centre of Singapore will brief on the status of a first-in-human clinical trial using an adenovirus under a protocol endorsed by the U.S. Food and Drug Administration ...

Amgen and AstraZeneca’s psoriasis drug beats blockbuster Stelara in head-to-head trial

John Carroll Amgen and its Big Pharma partner AstraZeneca have roped in another round of promising Phase III plaque psoriasis data for their IL-17 blockbuster contender brodalumab, ...

EMA adopts open trial data policy to begin Jan. 1

Emily Mullin The European Medicines Agency adopted a new policy on Oct. 2 that requires drug companies to make public certain clinical data that predicate drug approvals. FierceBiotech ...

Chikungunya vaccine shows antibody response in Phase I trial

Emily Mullin Following recent outbreaks in the Pacific and Caribbean, chikungunya virus has made its way to the U.S.–and drug developers have taken note of its continued spread. FierceBiotech ...

China sets trial date for GSK-tied investigators, says it will be ‘open’

Carly Helfand China will try two private investigators tied to GlaxoSmithKline's operations there in just over a week on charges of illegally purchasing personal information about ...

Quark’s RNAi treatment misses the mark in a Phase II kidney trial

Damian Garde Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with ...

UPDATED: Targacept’s litany of trial failures continues with yet another flop

John Carroll On Monday, Targacept reported that its midstage effort aimed at salvaging its lead drug flopped. Once partnered with AstraZeneca, which saw four late-stage studies for ...
Page 2 of 1212345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS